Hims & Hers Booms: Stellar Growth, But Are Margins a Concern?
🚀 Hims & Hers Health reported exceptionally positive Q1 results, with revenue soaring over 110% to more than $586 million and achieving a net income of nearly $50 million.
📈 The company raised its 2025 adjusted EBITDA forecast to between $295 million and $335 million, while maintaining its revenue guidance of $2.3 to $2.4 billion.
⚠️ Despite strong growth, Hims experienced a slight contraction in margins, and its Q2 adjusted EBITDA guidance ($60-70 million) indicates a sequential decrease, which appeared to concern the market.
HIMS Hits Key Support: Buy the Dip in This Growth Stock?
📉 HIMS stock has fallen significantly but is now testing a crucial long-term support level (40-week/200-day moving average), potentially offering an attractive entry point for investors monitoring technical levels.
💰 HIMS boasts impressive fundamentals, including strong revenue growth (77-95% recent quarterly growth), expected future profit increases (117% in 2025, 46% in 2026), and increasing institutional ownership, signaling underlying business strength.
🛡️ As a US-focused online pharmacy platform disrupting the sector, HIMS appears largely insulated from the direct impacts of the current tariff war, reducing a key market risk.
